BioCentury | Apr 7, 2020
Product Development

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

...hyperoxaluria (PH) programs. Dicerna will be responsible for the clinical development of liver disease candidates DCR-A1At...
BioCentury | Dec 15, 2018
Product Development

Extending Immunocore’s runway

The $100 million upfront payment from Immunocore Ltd.’s most recent deal with Roche's Genentech Inc. unit gives it enough cash to read out pivotal data from lead program IMCgp100, a catalyst that could help justify...
BioCentury | Jun 9, 2017
Clinical News

Aveo reports Phase I data for ficlatuzumab in SCCHN

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) reported data from 12 evaluable patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who were refractory to cetuximab in a Phase I trial showing that...
BioCentury | Jul 21, 2014
Clinical News

Rucaparib: Additional Phase I/II data

Final data from the dose-escalation Phase I portion of an open-label, U.S. and U.K. Phase I/II trial showed that ovarian cancer patients who received >=360 mg twice-daily oral rucaparib (n=12) had a disease control rate...
BioCentury | Oct 15, 2012
Clinical News

Belinostat: Interim Phase I/II data

Interim data from 20 STS patients in the Phase II portion of the open-label Phase I/II PXD101-CLN-14 trial showed that 1,000 mg/m 2 belinostat plus 75 mg/m 2 doxorubicin led to a disease control rate...
BioCentury | Jun 11, 2012
Clinical News

Tetraxetan clivatuzumab: Final Phase Ib/II data

Final data from 90 evaluable patients with advanced inoperable pancreatic cancer in an open-label, dose-escalation, U.S. Phase Ib/II trial showed that multiple cycles of clivatuzumab plus gemcitabine (n=31) led to a combined median overall survival...
BioCentury | Jun 13, 2011
Clinical News

Ganetespib: Additional Phase II data

Additional data from an open-label, U.S. Phase II trial in 76 evaluable patients showed that ganetespib produced an overall response rate (ORR) of 5.3% and a disease control rate (DCR) of 54% at week 8....
BioCentury | May 23, 2011
Clinical News

Cabozantinib: Interim Phase II data

Updated interim data from 51 evaluable patients in the cohort of subjects with advanced epithelial ovarian cancer in the lead-in stage of an ongoing, adaptive, international Phase II trial showed that once-daily oral cabozantinib produced...
BioCentury | May 20, 2011
Clinical News

Updated Phase II data for Exelixis' cabozantinib

Exelixis Inc. (NASDAQ:EXEL) will present updated interim data from a Phase II trial of cabozantinib ( XL184 ) at the American Society of Clinical Oncology meeting in Chicago in June, according to an abstract released ahead of...
BioCentury | Oct 18, 2010
Clinical News

Crizotinib: Updated Phase I data

Updated data from the expansion cohort of an open-label Phase I trial in 113 patients with advanced NSCLC carrying the ALK fusion gene showed that twice-daily 250 mg crizotinib produced a complete or partial response...
Items per page:
1 - 10 of 11